Researchers and translational teams often face significant hurdles when adopting multiplex immunofluorescence, frequently constrained by rigid operating models. This collaboration aims to lower those barriers by allowing labs to choose between running assays internally or leveraging Propath’s established facility in the United Kingdom. Propath brings over 35 years of experience in histopathology and spatial transcriptomics, providing a robust framework for clients needing support with antibody optimization, panel development, and GCP-compliant biomarker analysis.

Adrian Arechiga, Revolune’s Chief Commercial Officer, emphasized that the technology is designed to bridge the gap between primary antibody use and ready-to-use multiplex kits. For biopharma companies, the partnership offers a way to accelerate study timelines without the immediate overhead of internal infrastructure. Kelly Hunter, Chief Scientific Officer at Propath, noted that the model is particularly beneficial for organizations looking to evaluate new multiplex workflows while maintaining high standards of data interpretation. This initiative marks a significant expansion of Revolune’s service provider network, with plans to grow its geographic footprint further to meet evolving industry demand.